Aadi Bioscience (AADI) Competitors $2.05 +0.14 (+7.33%) As of 07/14/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AADI vs. FDMT, YMAB, ENGN, EPRX, GNFT, OGI, NLTX, PROK, ALMS, and ELDNShould you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), enGene (ENGN), Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), Organigram Global (OGI), Neoleukin Therapeutics (NLTX), ProKidney (PROK), Alumis (ALMS), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. Aadi Bioscience vs. Its Competitors 4D Molecular Therapeutics Y-mAbs Therapeutics enGene Eupraxia Pharmaceuticals GENFIT Organigram Global Neoleukin Therapeutics ProKidney Alumis Eledon Pharmaceuticals 4D Molecular Therapeutics (NASDAQ:FDMT) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Do analysts recommend FDMT or AADI? 4D Molecular Therapeutics presently has a consensus price target of $29.56, indicating a potential upside of 610.47%. Aadi Bioscience has a consensus price target of $1.67, indicating a potential downside of 18.70%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe 4D Molecular Therapeutics is more favorable than Aadi Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60Aadi Bioscience 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer FDMT or AADI? In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 0 mentions for Aadi Bioscience. 4D Molecular Therapeutics' average media sentiment score of 0.62 beat Aadi Bioscience's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Overall Sentiment 4D Molecular Therapeutics Positive Aadi Bioscience Neutral Is FDMT or AADI more profitable? Aadi Bioscience has a net margin of -246.06% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. 4D Molecular Therapeutics' return on equity of -33.26% beat Aadi Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-767,126.06% -33.26% -30.68% Aadi Bioscience -246.06%-71.87%-57.28% Which has more risk & volatility, FDMT or AADI? 4D Molecular Therapeutics has a beta of 2.81, indicating that its stock price is 181% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Which has stronger earnings & valuation, FDMT or AADI? Aadi Bioscience has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K4,818.32-$160.87M-$3.18-1.31Aadi Bioscience$25.07M2.02-$65.76M-$2.35-0.87 Do institutionals & insiders have more ownership in FDMT or AADI? 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Summary4D Molecular Therapeutics beats Aadi Bioscience on 10 of the 15 factors compared between the two stocks. Get Aadi Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AADI vs. The Competition Export to ExcelMetricAadi BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.63M$761.46M$5.53B$9.30BDividend YieldN/A4.84%4.59%4.03%P/E Ratio-0.901.4128.5619.60Price / Sales2.0227.11359.9473.66Price / CashN/A19.5624.7327.56Price / Book0.486.918.155.55Net Income-$65.76M-$4.17M$3.24B$257.73M7 Day Performance3.54%2.33%2.03%0.95%1 Month Performance4.59%1.35%8.29%10.68%1 Year Performance37.58%19.90%28.40%15.67% Aadi Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AADIAadi Bioscience0.3833 of 5 stars$2.05+7.3%$1.67-18.7%+23.2%$50.63M$25.07M-0.9040FDMT4D Molecular Therapeutics2.3867 of 5 stars$3.95-6.8%$29.56+648.2%-83.9%$196.42M$40K-1.24120News CoverageAnalyst ForecastYMABY-mAbs Therapeutics4.1553 of 5 stars$4.22-1.9%$15.60+269.7%-65.0%$194.72M$87.68M-6.59150Positive NewsENGNenGene2.8138 of 5 stars$3.81+0.3%$23.29+511.2%-63.2%$194.20MN/A-2.3131EPRXEupraxia Pharmaceuticals2.4047 of 5 stars$5.54+2.8%$11.00+98.6%+98.9%$193.81MN/A-7.2929Positive NewsGap UpGNFTGENFIT2.3158 of 5 stars$3.69-4.8%$13.00+252.7%-10.8%$193.49M$76.77M0.00120Gap UpOGIOrganigram Global1.1515 of 5 stars$1.39-2.8%N/A-12.7%$191.53M$117.47M13.90860NLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-49.7%$188.81MN/A-6.4690PROKProKidney3.5314 of 5 stars$0.61-4.8%$3.50+477.1%+57.0%$186.51M$306K-1.013News CoverageAnalyst ForecastGap UpALMSAlumis3.4563 of 5 stars$3.31-2.6%$22.86+590.5%-67.5%$184.98MN/A0.00N/ANews CoveragePositive NewsELDNEledon Pharmaceuticals1.8261 of 5 stars$3.11+1.0%$9.00+189.4%+53.9%$184.44MN/A-1.4810News CoverageAnalyst Revision Related Companies and Tools Related Companies FDMT Competitors YMAB Competitors ENGN Competitors EPRX Competitors GNFT Competitors OGI Competitors NLTX Competitors PROK Competitors ALMS Competitors ELDN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AADI) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
